Ligand Pharmaceuticals (LGND) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LGND shares.
View LGND analyst ratings or view top-rated stocks.

4 brokers have issued 12 month price targets for Ligand Pharmaceuticals' shares. Their LGND share price forecasts range from $90.00 to $144.00. On average, they anticipate the company's share price to reach $109.75 in the next twelve months. This suggests a possible upside of 86.5% from the stock's current price.
View analysts price targets for LGND or view top-rated stocks among Wall Street analysts.

Ligand Pharmaceuticals' stock was trading at $66.80 at the beginning of the year. Since then, LGND shares have decreased by 11.9% and is now trading at $58.86.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our LGND earnings forecast.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted its earnings results on Tuesday, August, 8th. The biotechnology company reported $1.42 EPS for the quarter, topping analysts' consensus estimates of $0.76 by $0.66. The biotechnology company had revenue of $26.37 million for the quarter, compared to the consensus estimate of $24.74 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 6.82% and a net margin of 14.54%. The business's revenue was down 47.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.14) EPS.

ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Franklin Genomic Advancements ETF (HELX), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

Ligand Pharmaceuticals updated its FY23 earnings guidance on Monday, September, 18th. The company provided EPS guidance of $5.10-5.25 for the period, compared to the consensus EPS estimate of $4.97. The company issued revenue guidance of $124-126 million, compared to the consensus revenue estimate of $127.17 million.

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.83%), State Street Corp (3.53%), Dimensional Fund Advisors LP (3.08%), Villere ST Denis J & Co. LLC (2.78%), Stephens Investment Management Group LLC (2.69%) and Chicago Capital LLC (2.46%). Insiders that own company stock include Andrew Reardon, Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis.
View institutional ownership trends.

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LGND stock can currently be purchased for approximately $58.86.

Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.02 billion and generates $196.24 million in revenue each year. The biotechnology company earns $-33,360,000.00 in net income (profit) each year or $1.44 on an earnings per share basis.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826.